Baird, Richard D <br/><br/>
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  11 2019 
 - 6598-6605 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-19-0508  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biomarkers, Tumor<br/>Breast Neoplasms--diagnosis<br/>Circulating Tumor DNA<br/>Female<br/>Humans<br/>Imidazoles--administration & dosage<br/>Middle Aged<br/>Mutation<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Oxazepines--administration & dosage<br/>Receptors, Estrogen--genetics<br/>Receptors, Progesterone--genetics<br/>Retreatment<br/>Tamoxifen--administration & dosage<br/>Treatment Outcome